Alzheimers would be a stupid target for ANP !
A lot of money, a lot of time, large trials and a biotech graveyard with 99% failure rate - leave that stuff to big pharma with money to burn.
ANP’s best to stick with rare diseases which i think they will - as is we still need to finding the funding for the IIB trial.
Where others have failed will Atl1102 succeed ?, page-9
-
- There are more pages in this discussion • 557 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.9¢ |
Change
-0.001(5.56%) |
Mkt cap ! $9.243M | |||
| Open | High | Low | Value | Volume |
| 0.9¢ | 0.9¢ | 0.9¢ | $1.109K | 126.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 9398424 | 0.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 948000 | 3 |
View Market Depth
| Last trade - 15.53pm 08/07/2025 (20 minute delay) ? |
| PER (ASX) Chart |